Abstract
OBJECTIVE
To test the hypothesis that prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population.
DESIGN
A multi-centre, randomised, double-blind, placebo-controlled trial.
SETTING
Twelve city hospitals in The Netherlands.
PARTICIPANTS
One hundred and sixty-eight women with a singleton pregnancy and a history of a spontaneous preterm delivery in the preceding pregnancy.
INTERVENTIONS
Clindamycin 2% vaginal cream, or placebo cream, administered daily for seven days at 26 and 32 weeks of gestation.
MAIN OUTCOME MEASURES
Spontaneous preterm birth at < 37 weeks, admission for threatened preterm labour, neonatal infectious morbidity.
RESULTS
In the intention-to-treat analysis no difference was found in overall preterm birth between clindamycin and placebo (23% vs 18%, respectively). In the subgroup who completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (1.4% in the placebo vs 9.0% in the clindamycin group; P < 0.05). The length of admissions for threatened preterm labour did not differ. More infectious neonatal morbidity was seen in the clindamycin group (5/83 vs 0/85; P < 0.05).
CONCLUSION
Clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labour. The neonatal infectious morbidity in the group treated with clindamycin was significantly higher and a major concern.
Pub Type(s)
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
TY - JOUR
T1 - Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.
AU - Vermeulen,G M,
AU - Bruinse,H W,
PY - 1999/7/31/pubmed
PY - 2000/6/10/medline
PY - 1999/7/31/entrez
KW - Antibiotics
KW - Demographic Factors
KW - Developed Countries
KW - Double-blind Studies
KW - Drugs
KW - Europe
KW - Netherlands
KW - Population
KW - Population Characteristics
KW - Pregnancy
KW - Pregnancy Outcomes
KW - Pregnant Women
KW - Premature Birth--prevention and control
KW - Reproduction
KW - Research Methodology
KW - Research Report
KW - Studies
KW - Treatment
KW - Western Europe
SP - 652
EP - 7
JF - British journal of obstetrics and gynaecology
JO - Br J Obstet Gynaecol
VL - 106
IS - 7
N2 - OBJECTIVE: To test the hypothesis that prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population. DESIGN: A multi-centre, randomised, double-blind, placebo-controlled trial. SETTING: Twelve city hospitals in The Netherlands. PARTICIPANTS: One hundred and sixty-eight women with a singleton pregnancy and a history of a spontaneous preterm delivery in the preceding pregnancy. INTERVENTIONS: Clindamycin 2% vaginal cream, or placebo cream, administered daily for seven days at 26 and 32 weeks of gestation. MAIN OUTCOME MEASURES: Spontaneous preterm birth at < 37 weeks, admission for threatened preterm labour, neonatal infectious morbidity. RESULTS: In the intention-to-treat analysis no difference was found in overall preterm birth between clindamycin and placebo (23% vs 18%, respectively). In the subgroup who completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (1.4% in the placebo vs 9.0% in the clindamycin group; P < 0.05). The length of admissions for threatened preterm labour did not differ. More infectious neonatal morbidity was seen in the clindamycin group (5/83 vs 0/85; P < 0.05). CONCLUSION: Clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labour. The neonatal infectious morbidity in the group treated with clindamycin was significantly higher and a major concern.
SN - 0306-5456
UR - https://www.unboundmedicine.com/medline/citation/10428520/Prophylactic_administration_of_clindamycin_2_vaginal_cream_to_reduce_the_incidence_of_spontaneous_preterm_birth_in_women_with_an_increased_recurrence_risk:_a_randomised_placebo_controlled_double_blind_trial_
L2 - https://medlineplus.gov/pretermlabor.html
DB - PRIME
DP - Unbound Medicine
ER -